GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Fangzhou Inc (HKSE:06086) » Definitions » EV-to-EBITDA

Fangzhou (HKSE:06086) EV-to-EBITDA : -5.68 (As of Jun. 02, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Fangzhou EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fangzhou's enterprise value is HK$5,212 Mil. Fangzhou's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-918 Mil. Therefore, Fangzhou's EV-to-EBITDA for today is -5.68.

The historical rank and industry rank for Fangzhou's EV-to-EBITDA or its related term are showing as below:

HKSE:06086' s EV-to-EBITDA Range Over the Past 10 Years
Min: -51.69   Med: -28.55   Max: -1.95
Current: -5.68

During the past 4 years, the highest EV-to-EBITDA of Fangzhou was -1.95. The lowest was -51.69. And the median was -28.55.

HKSE:06086's EV-to-EBITDA is ranked worse than
100% of 499 companies
in the Healthcare Providers & Services industry
Industry Median: 12.21 vs HKSE:06086: -5.68

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-02), Fangzhou's stock price is HK$3.96. Fangzhou's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.687. Therefore, Fangzhou's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Fangzhou EV-to-EBITDA Historical Data

The historical data trend for Fangzhou's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fangzhou EV-to-EBITDA Chart

Fangzhou Annual Data
Trend Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
- - - -9.73

Fangzhou Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBITDA Get a 7-Day Free Trial - - - - -9.73

Competitive Comparison of Fangzhou's EV-to-EBITDA

For the Pharmaceutical Retailers subindustry, Fangzhou's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fangzhou's EV-to-EBITDA Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Fangzhou's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fangzhou's EV-to-EBITDA falls into.


;
;

Fangzhou EV-to-EBITDA Calculation

Fangzhou's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=5212.455/-917.568
=-5.68

Fangzhou's current Enterprise Value is HK$5,212 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fangzhou's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-918 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fangzhou  (HKSE:06086) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Fangzhou's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.96/-0.687
=At Loss

Fangzhou's share price for today is HK$3.96.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fangzhou's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was HK$-0.687.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Fangzhou EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Fangzhou's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Fangzhou Business Description

Traded in Other Exchanges
N/A
Address
4th Street, Floor 1-2, Building S, Kehui Jingu, No. 99, Science Avenue, Luogang Science City, Huangpu District, Guangdong Province, Guangzhou, CHN
Fangzhou Inc is a online chronic disease management platform in China. It has focus on chronic disease management to address the needs of patients with chronic diseases, such as hypertension, cardiovascular and respiratory chronic diseases. The company provide comprehensive medical services and online retail pharmacy services through Jianke Platform. The principal segment of the group are online retail pharmacy services, comprehensive medical services and customized content and marketing solutions. Key revenue is generated from Online retail pharmacy services.
Executives
Asia Tech Holdings Limited 2201 Interest of corporation controlled by you
Vistra Trust (hong Kong) Limited 2301 Trustee
Crescent China Investment Management Ltd. 2102 Investment manager
Hand David Mckee 2201 Interest of corporation controlled by you
Rojanavanichkul Danai 2201 Interest of corporation controlled by you
Veneto Holdings Ltd. 2201 Interest of corporation controlled by you
Tech-med Cayman Iii Ltd. 2201 Interest of corporation controlled by you
Tech-med Investments (s) Pte. Ltd. 2101 Beneficial owner
Cp Pharmatech Singapore Pte. Ltd. 2101 Beneficial owner
Asia Tech Investments Ltd. 2101 Beneficial owner
Crescent Acso Investment Management Ltd 2201 Interest of corporation controlled by you
Crescent Trident Singapore Pte. Ltd. 2101 Beneficial owner
Xie Fangmin 2201 Interest of corporation controlled by you
Zhou Feng 2201 Interest of corporation controlled by you
Fangrong Management Limited 2101 Beneficial owner

Fangzhou Headlines

No Headlines